Ameriprise
STOK icon

Ameriprise’s Stoke Therapeutics STOK Stock Holding History

Ameriprise’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$668K Buy
20,423
+2,310
+13% +$74.1K ﹤0.01% 3578
2026
Q1 		$590K Sell
18,113
-2,963
-14% -$97.2K ﹤0.01% 3529
2025
Q4 		$669K Buy
21,076
+80
+0.4% +$2.4K ﹤0.01% 3517
2025
Q3 		$493K Buy
+20,996
New +$360K ﹤0.01% 3635
2025
Q1 		– Sell
-10,527
Closed -$116K – 4145
2024
Q4 		$116K Sell
10,527
-3,788
-26% -$46.5K ﹤0.01% 3937
2024
Q3 		$176K Buy
14,315
+4,010
+39% +$56.8K ﹤0.01% 3774
2024
Q2 		$139K Buy
+10,305
New +$139K ﹤0.01% 3737
2024
Q1 		– Sell
-22,054
Closed -$116K – 3954
2023
Q4 		$116K Sell
22,054
-10,978
-33% -$46.9K ﹤0.01% 3798
2023
Q3 		$130K Buy
+33,032
New +$217K ﹤0.01% 3757

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise's STOK Position: Q2 2026 in Review

Ameriprise increased its Stoke Therapeutics (STOK) stake by 13% in Q2 2026, buying an estimated $74.1K and bringing the position to 20,423 shares worth $668K. The position accounts for ﹤0.01% of the portfolio, ranked #3578.

Ameriprise first reported a position in STOK in Q3 2023 and has held it in 9 quarters since. The position peaked at $669K in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Ameriprise held 20,423 shares of Stoke Therapeutics worth $668K as of Q2 2026.
  • Ameriprise bought 2,310 Stoke Therapeutics shares in Q2 2026, an estimated $74.1K.
  • Stoke Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3578 holding.
  • Ameriprise first reported a position in Stoke Therapeutics in Q3 2023 and has held it in 9 quarters since.
  • Ameriprise's Stoke Therapeutics position peaked at $669K in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.